Compare Adaptive Biotechnologies Corp (ADPT) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Thomson Reuters Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while Thomson Reuters Corp trades at $88.68 (market cap $39.64B). The key difference: Thomson Reuters Corp is far larger — about 11.9× Adaptive Biotechnologies Corp's market cap, and Thomson Reuters Corp pays a 2.89% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TRI | |
|---|---|---|
Market Cap | $3.33B | $39.64B |
Sector | Health | Industrials |
52-Week High | $22.37 | $214.21 |
52-Week Low | $10.24 | $76.55 |
Enterprise Value | $3.19B | $41.59B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Thomson Reuters (TRI) trades at $90.76, up 1.74% with bullish technical indicators and strong analyst support. The company reported Q1 2026 EPS of $1.23, beating estimates, while revenue reached $7.48B in 2025. Recent corporate actions include a special dividend and reverse stock split. Technical analysis shows resistance near $92 with RSI indicating potential overbought conditions.
Outlook remains positive with a consensus price target of $129.96, though risks include AI implementation challenges and competitive pressures. Revenue growth is steady, but net income margin compression from 39.66% in 2023 to 20.09% in 2025 warrants monitoring. Institutional sentiment is bullish with 51.85% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
